Health Reform Bill Downsizing Would Send Pharma Back To Bargaining Table
This article was originally published in The Tan Sheet
Executive Summary
The biopharmaceutical industry will look to renegotiate its financial contribution to health reform if congressional Democratic leaders determine that a much more modest bill is the best way forward following the loss of their 60-seat super-majority in the Senate
You may also be interested in...
Pharma's Reform Bounce: How Big A Boost Will $80 Bil. Buy
The introduction of the Senate Finance Committee's health care proposal turns the focus from what the pharmaceutical industry will contribute to reform efforts toward what manufacturers stand to gain
Dollars For Donuts: PhRMA's $80 Bil. Coup In Health Care Reform
PhRMA's commitment to contribute $80 billion toward health systems savings over the next 10 years looks like an important tactical win for the brand name industry entering the critical phase of the health reform debate
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC